Global Blood Collection Tubes for Liquid Biopsy Market Strategic Research Report

Scope of the Report

The global Blood Collection Tubes for Liquid Biopsy market size is predicted to grow from US$ 157 million in 2025 to US$ 501 million in 2032; it is expected to grow at a CAGR of 18.2% from 2026 to 2032.

Blood Collection Tubes for Liquid Biopsy are specialized in vitro diagnostic consumables designed to collect and stabilize whole blood samples for the preservation of circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), cfRNA, and circulating tumor cells (CTCs). Unlike conventional blood tubes, these products inhibit cell lysis and enzymatic degradation post-collection, ensuring high sample integrity critical for non-invasive early cancer detection, treatment monitoring, and therapy selection. Common types include cfDNA stabilizing EDTA tubes and CTC capture tubes, which are compatible with platforms like NGS, high-throughput PCR, and droplet digital PCR (ddPCR).

The rapid advancement of global precision oncology is the key driver of the liquid biopsy blood collection tube market. Annual reports from companies such as Illumina, Guardant Health, and Exact Sciences reveal an increasing reliance on high-quality blood samples, boosting demand for premium sample collection consumables. Simultaneously, government initiatives such as the U.S. “Cancer Moonshot” and China’s “Thousand Counties Project” are pushing early cancer screening into public health systems, making blood collection tubes strategic consumables. Emerging use cases in chronic disease monitoring, prenatal testing, and at-home sampling are also expanding market potential.

Despite robust growth, the market faces several hurdles including high regulatory barriers, long validation cycles for stability, and strict requirements for platform compatibility. Reports from Biocept and Natera indicate that products must comply with FDA and CE-IVDR standards, increasing development costs. The presence of low-cost alternatives intensifies price-based competition. In addition, maintaining sample integrity during logistics—especially under cold-chain requirements—poses challenges for adoption in rural hospitals and remote sampling scenarios.

Liquid biopsy tubes are currently used primarily in cancer screening and companion diagnostics, but their application is expanding to multi-cancer early detection (MCED), minimal residual disease (MRD) testing, and AI-powered diagnostics. Guardant Health’s 2024 annual report notes collaborations with hospitals and pharmaceutical companies to build large-scale biobanks, indicating a shift in customer base from academic to commercial use including CROs, CDMOs, and biopharma firms. With the rise of at-home sampling and decentralized diagnostics, the industry is moving toward portable, ambient-stable tube designs to meet diversified market needs.

This report presents a comprehensive overview of the global Blood Collection Tubes for Liquid Biopsy market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Plastic
• Glass

Segment by Application

• IVD
• Research Use

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Collection Tubes for Liquid Biopsy market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in IVD, Research Use evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact